Overview
One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
Background
One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
Indication
For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies; chronic simple (open-angle) glaucoma
Associated Conditions
- Acute angle-closure glaucoma
- Edema
- Familial periodic paralysis
- Generalized Tonic-Clonic Seizures
- Metabolic Alkalosis
- Open Angle Glaucoma (OAG)
- Other and unspecified effects of high altitude
- Cystine renal calculi
- Drug-induced edema
- Nonuveitic secondary glaucoma
- Salicylate intoxication
Clinical Trials
View More Clinical Trials
Sign in to access the complete clinical trial database with detailed study information.
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2017/06/06 | Phase 4 | Completed | |||
2017/06/06 | Phase 4 | Completed | |||
2017/06/01 | Phase 4 | Completed | |||
2017/05/25 | Phase 4 | Completed | |||
2017/05/24 | Phase 4 | Completed | |||
2017/05/17 | Phase 4 | Completed | |||
2017/05/16 | Phase 1 | Completed | Grant S Lipman | ||
2017/04/11 | Not Applicable | Completed | |||
2017/01/05 | Phase 1 | Completed | |||
2016/12/29 | Not Applicable | Completed | Post Graduate Institute of Medical Education and Research, Chandigarh |
FDA Drug Approvals
View More FDA Approvals
Sign in to access additional FDA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
Nostrum Laboratories, Inc. | 29033-030 | ORAL | 500 mg in 1 1 | 12/18/2018 | |
AvKARE | 42291-090 | ORAL | 250 mg in 1 1 | 1/9/2024 | |
PD-Rx Pharmaceuticals, Inc. | 72789-237 | ORAL | 250 mg in 1 1 | 2/16/2024 | |
Micro Labs Limited | 42571-243 | ORAL | 500 mg in 1 1 | 5/23/2022 | |
Heritage Pharmaceuticals Labs Inc. d/b/a Avet Pharmaceuticals Labs Inc. | 23155-313 | INTRAVENOUS | 500 mg in 5 mL | 8/1/2022 | |
AvPAK | 50268-042 | ORAL | 500 mg in 1 1 | 1/9/2024 | |
Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. | 23155-288 | ORAL | 250 mg in 1 1 | 8/1/2022 | |
A-S Medication Solutions | 50090-4511 | ORAL | 125 mg in 1 1 | 10/10/2022 | |
TRUPHARMA, LLC | 52817-201 | ORAL | 250 mg in 1 1 | 6/21/2022 | |
Bryant Ranch Prepack | 63629-1195 | ORAL | 250 mg in 1 1 | 10/18/2023 |
EMA Drug Approvals
View More EMA Approvals
Sign in to access additional EMA-approved drug information with detailed regulatory data.
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
View More HSA Approvals
Sign in to access additional HSA-approved drug information with detailed regulatory data.
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
View More NMPA Approvals
Sign in to access additional NMPA-approved drug information with detailed regulatory data.
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
View More PPB Approvals
Sign in to access additional PPB-approved drug information with detailed regulatory data.
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
View More TGA Approvals
Sign in to access additional TGA-approved drug information with detailed regulatory data.
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |